Pill Identifier App

Generic Aricept ODT Availability

See also: Generic Aricept

Aricept ODT is a brand name of donepezil, approved by the FDA in the following formulation(s):

ARICEPT ODT (donepezil hydrochloride - tablet, orally disintegrating;oral)

  • Manufacturer: EISAI INC
    Approval date: October 18, 2004
    Strength(s): 5MG [AB], 10MG [RLD] [AB]

Has a generic version of Aricept ODT been approved?

A generic version of Aricept ODT has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Aricept ODT and have been approved by the FDA:

donepezil hydrochloride tablet, orally disintegrating;oral

  • Manufacturer: BARR
    Approval date: November 26, 2010
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: MACLEODS PHARMS LTD
    Approval date: December 14, 2012
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: SANDOZ
    Approval date: May 10, 2011
    Strength(s): 5MG [AB], 10MG [AB]
  • Manufacturer: ZYDUS PHARMS USA INC
    Approval date: May 10, 2011
    Strength(s): 5MG [AB], 10MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aricept ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Rapidly disintegrable tablet containing polyvinyl alcohol
    Patent 7,727,548
    Issued: June 1, 2010
    Inventor(s): Morita; Yutaka & Yasui; Masanobu & Ohwaki; Takayuki & Tsushima; Yuki
    Assignee(s): Eisai R&D Management Co., Ltd.
    The present invention provides a quickly disintegrating tablet which has quick disintegrability and solubility in an oral cavity, and does not have uncomfortable tastes such as bitterness, has a small variation of a tablet physical property even in storage under a humidifying condition, and has substantially no change in a medicine content in the tablet and tablet appearance and which is superior in stability; and a manufacturing method of the tablet. That is, it provides: a quickly disintegrating tablet which is prepared by blending a medicine with a saccharide and polyvinyl alcohol, which has small variations of tablet weight, tablet hardness, tablet diameter and tablet thickness, and which is superior in medicine stability in the tablet; and a manufacturing method of the tablet.
    Patent expiration dates:
    • June 23, 2022
      Drug product
  • Oral pharmaceutical preparations decreased in bitterness by masking
    Patent 7,727,552
    Issued: June 1, 2010
    Inventor(s): Ukai; Koji & Hrada; Tsutomu & Suzuki; Yasuyuki
    Assignee(s): Eisai R&D Management Co., Ltd.
    A composition of an oral medicine or an oral medicine which can prevent an unpleasant taste of the medicine is herein disclosed. It is granules, powders, syrups and the like which is prevented from an unpleasant taste, comprising a basic medicine having an unpleasant taste and an anionic polymer such as carrageenan.
    Patent expiration dates:
    • March 26, 2018
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
ABProducts meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.